Pharma Tips

Diabetes Vaccine trial posts Positive Results

By: Pharma News | Views: 1182 | Date: 08-Jul-2013

A groundbreaking new study suggests that the body’s immune system can be taught to reverse the effects of type 1 diabetes.The early-stage study, published this week in Science Translational Medicine, was conducted on 80 type 1 patients using the treatment TOL-3021.This DNA vaccine is made up of a small round piece of DNA called a plasmid, which is genetically engineered to shut down only the immune system cells causing harm, while leaving the rest of the immune system intact.

Diabetes Vaccine trial posts Positive Results

Vaccine image

A groundbreaking new study suggests that the body’s immune system can be taught to reverse the effects of type 1 diabetes.

The early-stage study, published this week in Science Translational Medicine, was conducted on 80 type 1 patients using the treatment TOL-3021.

This DNA vaccine is made up of a small round piece of DNA called a plasmid, which is genetically engineered to shut down only the immune system cells causing harm, while leaving the rest of the immune system intact.

In patients with type 1 diabetes, the immune system destroys beta cells in the pancreas, meaning they are unable to produce enough insulin.

The vaccine was targeted to the specific white blood cells which attack beta cells. The trial showed that after patients were given weekly injections for three months, the levels of those white blood cells fell.

The study and vaccine have been developed by teams from Leiden University Medical Centre in the Netherlands and Stanford University in California.

“The idea here is to turn off just the rogue immune cells that are attacking the pancreas and killing the beta cells that secrete insulin,” said Stanford Professor Dr Lawrence Steinman, one of the study’s senior authors and co-founder of firm Tolerion that was recently formed to commercialise the vaccine.

The vaccine also reduced the number of killer immune cells known as T cells. Patients who got the active vaccine had higher levels of C-peptides, suggesting the presence of more working beta cells.

Steinman told Reuters that the vaccine is far from commercial use, but the study is promising enough to do a bigger trial. “So far, it looks like it is doing what we want,” he said.

He added that ultimately, the hope is to develop an effective vaccine that could be given to individuals who are genetically predisposed to develop the condition.

The World Health Organization estimates that about 10% of the 350 million people in the world with diabetes have the type 1 variety - most have type 2, which is associated with obesity and lack of exercise, and is increasing exponentially year-on-year.


Previous Page Next Page

People Searching On This Page:

Related Pages


The Whole World Is Celebrating This News: Diabetes Vaccine Officially Announced

The Whole World Is Celebrating This News: Diabetes Vaccine Officially Announced

News | Pharmaceutical Drugs
Date:
10-Feb-2017  Views: 7232

In the United States alone, 1.25 million people suffer from type 1 diabetes. A vaccine used over 100 years ago for tuberculosis (bacillus Calmette-Gue ...
Work as MPHW (M), Pharmacist (27 posts) - Government Jobs

Work as MPHW (M), Pharmacist (27 posts) - Government Jobs

Jobs | Pharmacist Jobs
Date:
02-Jul-2013  Views: 3717

Applications in the prescribed proforma are invited from eligible candidates for following posts under the Chief District Medical Officer, Khordha to ...
Fish Oil may help fight against Type 2 diabetes

Fish Oil may help fight against Type 2 diabetes

News | R & D
Date:
27-May-2013  Views: 1617

Widely-used fish oil supplements modestly increase amounts of a hormone that is associated with lower risk of diabetes and heart disease, according to ...
Merck & Co and Pfizer Join Forces on Diabetes Pill

Merck & Co and Pfizer Join Forces on Diabetes Pill

News | Pharma Companies
Date:
02-May-2013  Views: 1324

Drug giants Merck & Co and Pfizer have formed a new alliance to jointly develop and commercialize the latter's ertugliflozin for the treatment of type ...
Amgen announces top-line results of phase 3 trial in melanoma

Amgen announces top-line results of phase 3 trial in melanoma

News | Pharma Companies
Date:
27-Apr-2013  Views: 896

Amgen (NASDAQ:AMGN) announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

98  + 9 =     
Comments

Google : 66 times | Yahoo : 27 times | Bing : 12 times |